Results 21 to 30 of about 12,502 (244)

Prevention of acute kidney injury and protection of renal function in the intensive care unit : update 2017 [PDF]

, 2017
Background: Acute kidney injury (AKI) in the intensive care unit is associated with significant mortality and morbidity. Objectives: To determine and update previous recommendations for the prevention of AKI, specifically the role of fluids, diuretics ...
Druml, W, Forni, LG, Groeneveld, ABJ, Honore, PM, Hoste, Eric, Joannidis, M, Ostermann, M, Oudemans-van Straaten, HM, Schetz, Mathias   +8 more
core   +11 more sources

Impact of Pre-Heart Transplant Levosimendan Administration on Post-Transplant Vasoplegia and Primary Graft Dysfunction. [PDF]

Clin Transplant
ABSTRACT Introduction Levosimendan, a calcium‐sensitizing inotropic agent, is used in patients with advanced heart failure (HF) awaiting heart transplantation (HT). Its prolonged effects, due to an active metabolite, may influence post‐transplant vasodilation, particularly when administered shortly before HT.
Guzman-Bofarull J, Martín-Centellas A, Couto-Mallon D, Borràs R, Arenas-Loriente A, Rivas-Lasarte M, Segovia-Cubero J, Crespo-Leiro MG, García-Álvarez A, Farrero M.   +9 more
europepmc   +2 more sources

Understanding the Clinical Use of Levosimendan and Perspectives on its Future in Oncology

Biomolecules, 2023
Drug repurposing, also known as repositioning or reprofiling, has emerged as a promising strategy to accelerate drug discovery and development. This approach involves identifying new medical indications for existing approved drugs, harnessing the ...

semanticscholar   +1 more source

Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post‐discharge period: The multinational randomized LeoDOR trial

European Journal of Heart Failure, 2023
The LeoDOR trial explored the efficacy and safety of intermittent levosimendan therapy in the vulnerable phase following a hospitalization for acute heart failure (HF).
G. Pölzl, J. Altenberger, J. Comín-Colet, J. Delgado, F. Fedele, M. García-González, F. Gustafsson, J. Masip, Z. Papp, S. Störk, H. Ulmer, S. Maier, B. Vrtovec, G. Wikström, E. Zima, A. Bauer   +15 more
semanticscholar   +1 more source

Levosimendan Reverses Cardiac Malfunction and Cardiomyocyte Ferroptosis During Heart Failure with Preserved Ejection Fraction via Connexin 43 Signaling Activation

Cardiovascular Drugs and Therapy, 2023
Purpose In recent decades, the occurrence of heart failure with preserved ejection fraction (HFpEF) has outweighed that of heart failure with reduced ejection fraction by degrees, but few drugs have been demonstrated to improve long-term clinical ...
Li-li Zhang, Gui-hao Chen, Rui-jie Tang, Y. Xiong, Qi Pan, Wenyang Jiang, Zhaoting Gong, Cheng Chen, Xiaosong Li, Yuejin Yang   +9 more
semanticscholar   +1 more source

Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO‐D registry

ESC Heart Failure, 2023
Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term.
D. Dobarro, V. Donoso-Trenado, E. Solé-González, C. Moliner-Abós, J. M. García-Pinilla, S. López-Fernández, S. Ruiz-Bustillo, C. Díez-López, J. Castrodeza, A. Mendez-Fernández, David Vaqueriza-Cubillo, M. Cobo-Marcos, Javier Tobar, Igor Sagasti-Aboitiz, Mireia Rodriguez, V. Escolar, A. Abecia, P. Codina, I. Gómez-Otero, F. Pastor, R. Marzoa-Rivas, E. González-Babarro, J. de Juan-Bagudá, M. Melendo-Viu, Fernando de Frutos, J. González-Costello   +25 more
semanticscholar   +1 more source

Overview of the current use of levosimendan in France: a prospective observational cohort study

Annals of Intensive Care, 2023
Background Following the results of randomized controlled trials on levosimendan, French health authorities requested an update of the current use and side-effects of this medication on a national scale.
B. Cholley, M. Bojan, B. Guillon, E. Besnier, Mathieu Mattéi, B. Levy, Alexandre Ouattara, N. Tafer, C. Delmas, D. Tonon, B. Rozec, J. Fellahi, Pascal Lim, François Labaste, F. Roubille, T. Caruba, P. Mauriat, Olivier Berthomieu Anne-Marie Blanchart Adrien Pierre Caus Barbot Laurent Besselat Katrien Bougle Bourgoin Ar, Olivier Barbot, Berthomieu Laurent, Anne-Marie Besselat, Blanchart Katrien, Adrien Bouglé, P. Bourgoin, Causeret Arnaud, H. Charbonneau, M. Cristinar, O. Desebbe, Veldat Eljezi, T. Genet, Maxime Grenier, P. Guinot, S. Lebel, Yael Levy, F. Lion, J. Mansourati, S. Marlière, Anne-Céline Martin, A. Mebazaa, Usman Mohammad, J. Monségu, Nicolas Nessler, I. Orsel, E. Puymirat, M. Recher, S. Soussi, Vincent Troussard, S. Uhry, X. Zirphile   +48 more
semanticscholar   +1 more source

Meta-Analysis of the Efficacy of Levosimendan in the Treatment of Severe Sepsis Complicated with Septic Cardiomyopathy.

Heart Surgery Forum, 2023
INTRODUCTION Sepsis is a medical condition characterized by acute organ dysfunction and uncontrolled inflammation. Organ dysfunction in sepsis is the primary cause of mortality in patients with myocardial dysfunction.
Qiongchan Guan, Chuang Zhang, Binbin Li, Daochao Huang, Aiming Li, Jie Qin, Xianhuan Zhang   +6 more
semanticscholar   +1 more source

Levosimendan in the Treatment of Patients with Severe Septic Cardiomyopathy

Life, 2023
(1) Background: The optimal treatment of septic cardiomyopathy (SCM) remains questionable. The aim of the study was to compare the treatment of SCM based on levosimendan versus the best available therapy.
Vasiliki Tsolaki, George E. Zakynthinos, J. Papanikolaou, Vasileios Vazgiourakis, Kyriaki Parisi, George Fotakopoulos, D. Makris, E. Zakynthinos   +7 more
semanticscholar   +1 more source

Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

Critical Care, 2020
Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock.
Enrique Guilherme, Matthias Jacquet-Lagrèze, Matteo Pozzi, Felix Achana, Xavier Armoiry, Jean-Luc Fellahi   +5 more
doaj   +1 more source